Chemoimmunotherapy for ALK+ ALCL that has come back
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of chemotherapy and immunotherapy for children and adults with a type of lymphoma called ALK-positive anaplastic large cell lymphoma that has returned or not responded to previous treatment. The goal is to see if this new approach can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 10 kilograms (about 22 pounds).
- Your lymphoma must be ALK-positive anaplastic large cell lymphoma that has come back or is not responding to treatment.
- You must have adequate organ function as determined by your doctor.
- You must be able to perform daily activities with minimal help (performance status 60 or above).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral targeted drugs—alectinib and duvelisib—for people whose ALK-positive anaplastic large cell lymphoma has come back or not responded after at least one prior chemotherapy. The goal is to see if this combination can help control the cancer.
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Hear when a new Anaplastic Large Cell Lymphoma, ALK-Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.